Spherix Inc., an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, and biotechnology companies, announced positive interim Phase 3 clinical results for the use of D-tagatose for treatment of type 2 diabetes patients.
D-tagatose is a novel and natural oral agent being developed as an oral, monotherapy treatment for glycemic control in patients with type 2 diabetes. D-tagatose prevents the stimulation of insulin secretion, avoiding beta cell exhaustion and naturally lowers blood glucose levels. The net effect is to shift or control blood sugar, HbA1c, and body weight at, or closer to normal, healthy levels.
D-tagatose has an established safety profile as an artificial sweetener and has been recognized by the U.S. Food and Drug Administration substance for use in food and beverages since 2001.
The results show a decrease in HbA1c levels in the participants taking D-tagatose compared to the control group. The Type 2 diabetics taking D-tagatose also showed better cholesterol levels and a decrease in BMI (Body Mass Index).
